CompuMed debuted its digital OsteoView 2000 bone densitometry scanner at the annual meeting of the American Society of Bone and Mineral Research held last week. OsteoView 2000 will allow diagnosis of both osteoporosis and arthritis, according to the
CompuMed debuted its digital OsteoView 2000 bone densitometry scanner at the annual meeting of the American Society of Bone and Mineral Research held last week. OsteoView 2000 will allow diagnosis of both osteoporosis and arthritis, according to the Manhattan Beach, CA-based company.
The scanner leverages off a set of image processing and segmentation tools developed by CompuMed, as well as direct digital x-ray capture technology developed by Varian Associates and Xerox under a grant from the U.S. Defense Advanced Research Projects Agency (DARPA). CompuMed has received exclusive rights to the technology in the fields of appendicular bone mass measurement and automated arthritis detection, according to CompuMed. Clinical trials will begin in October for OsteoView 2000, and the company expects to receive Food and Drug Administration 510(k) clearance in 1998.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.